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Abstract
Introduction: Amyloidosis  is a disorder of protein 
folding in which  normally soluble proteins undergo 
conformational changes and are deposited in the 
extracellular space in an abnormal fibrillar form. 
Accumulation of these fibrils causes progressive 
disruption of the structure and function of tissues and 
organs, and the systemic forms of amyloidosis are 
frequently fatal. The conditions that underlie amyloid 
deposition may be either acquired or hereditary. 
Amyloid-A (AA) amyloidosis is the most common form 
of systemic amyloidosis worldwide, AA amyloidosis 
occurs in the course of chronic inflammatory diseases, 
hereditary periodic fevers, and with certain neoplasms 
such as Hodgkin disease and renal cell carcinoma. 
Amyloidosis due to rheumatic heart disease (RHD) is not 
common but can be seen. We report here a patient with 
RHD and AA renal amyloidosis.
Case Report: we present a 30 year-old Egyptian 
male with a history of RHD, accidently discovered 
to have nephrotic range proteinuria and rising serum 
creatinine. Serology studies were negative or normal, 
including antinuclear antibody (ANA) and antineutrophil 
cytoplasmic antibody (ANCA). C3 and C4 complement 
levels were normal. Kidney biopsy revealed AA renal 
amyloidosis. CT chest and abdomen revealed bilateral 
hilar and mediastinal lymphadenopathy and para-aortic 
lymph nodes. Endobronchial biopsy and bronchoalveolar 
lavage revealed non-specific chronic inflammatory 
changes. The patient’s secondary amyloidosis was 
presumed to be related to the long standing RHD after 
exclusion of other causes of secondary amyloidosis. 
The patient finally died due to heart failure and acute 
pulmonary edema.  
Conclusion: Long standing RHD can lead to secondary 
AA amyloidosis.
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Introduction
Amyloidosis is a disorder of protein folding in which 
normally soluble proteins undergo conformational 
changes and are deposited in the extracellular space in 
an abnormal fibrillar form. Accumulation of these fibrils 
causes progressive disruption of the structure and function 
of tissues and organs, and the systemic (generalized) 
forms of amyloidosis are frequently fatal. The conditions 
that underlie amyloid deposition may be either acquired 
or hereditary, and at least 20 different proteins can form 
amyloid fibrils in vivo [1]. 
Renal dysfunction is one of the most common presenting 
features of patients with systemic amyloidosis, and 
amyloid accumulation is the major pathological finding 
in approximately 2.5% of all native renal biopsies. 
Most such patients have either reactive systemic (AA) 
amyloidosis or monoclonal immunoglobulin light-
chain (AL) amyloidosis, but in few cases, the disease is 
hereditary [2]. 
The spectrum of renal symptoms and signs in 
amyloidosis is variable such as isolated proteinuria, 
nephrotic syndrome, hypertension, hypotension and 
renal insufficiency. The kidneys are affected in almost all 
patients with AA amyloidosis but less frequently in AL 
amyloidosis [3].
Here we report a patient with long standing mitral and 
tricuspid valve disease due to rheumatic heart disease 
(RHD) and renal AA amyloidosis.
Case report
A  thirty year- old Egyptian male  with a history of mitral 
and tricuspid valve disease due to long standing RHD 
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Mitral valve replacement was considered to have an 
inappropriately high risk because of severe pulmonary 
hypertension. The patient received conservative treatment 
in the form of lisinopril 20 mg/day, alphacalcidol 0.25 
mcg/day, caltrate 600 mg twice daily, furosemide 40 mg 
daily and colchicine 1.5 mg twice daily. Colchicine was 
stopped after two months due to deteriorating kidney 
function and diarrhea. As there was no clinical evidence 
of rheumatoid arthritis or inflammatory bowel disease 
and after the exclusion of tuberculosis and malignancy, 
the patient’s secondary amyloidosis was presumed to be 
related to the long standing rheumatic heart disease. 
The patient presented nine months later with acute 
pulmonary edema, hypotension, potassium level of 
7.0 mmol/L and serum creatinine concentration of 6 mg/
dL. Urgent hemodialysis was initiated, but unfortunately 
the patient expired due to heart failure and acute 
pulmonary edema.  
Discussion
Amyloid-A (AA) amyloidosis is the most common form 
of systemic amyloidosis worldwide. It is characterized by 
extracellular tissue deposition of fibrils that are composed 
of fragments of serum amyloid A (SAA) protein, a major 
acute-phase reactant protein, produced predominantly 
by hepatocytes. AA amyloidosis occurs in the course of 
a chronic inflammatory disease of either infectious or 
noninfectious etiology, hereditary periodic fevers, and 
with certain neoplasms such as Hodgkin disease and 
renal cell carcinoma [4].
In developing countries, the most common trigger of 
AA amyloidosis is chronic infection; in industrialized 
societies, rheumatic diseases, such as rheumatoid arthritis 
(RA), are the usual stimulus. The United States is a major 
exception to this in that immunoglobulin-related amyloid 
light chain type (AL) of amyloidosis is more frequent than 
AA as the cause of systemic amyloid deposition [5]. 
In AA amyloidosis, the kidney, liver, and spleen are the 
major sites of involvement. The tissue fibril consists of 
a 7500-dalton cleavage product of the SAA protein, an 
acute-phase protein produced in numerous tissues. The 
major source of the circulating protein is the hepatocyte. 
Under the influence of the inflammatory cytokine 
interleukin (IL-6), hepatic transcription of the messenger 
ribonucleic acid (mRNA) for SAA may increase 
1000-fold when exposed to an inflammatory stimulus [5].
Intact circulating SAA (molecular weight 12,500 dalton) 
is complexed with high-density lipoproteins (HDL). 
During the course of inflammation, the apolipoprotein 
SAA (apoSAA) apparently displaces apolipoprotein A1 
(apoA1) from the HDL particles and facilitates HDL-
cholesterol uptake by macrophages [5]. 
Several lines of evidence have indicated that the 
conversion of SAA into amyloid fibrils occurs through its 
specific interaction with heparan sulphate, a ubiquitously 
expressed glycosaminoglycan component of the 
extracellular matrix [6].
In general, secondary amyloidosis shortened the median 
life span 7.7 years, and survival strongly depended 
on controlling the underlying inflammatory process. 
Amyloid deposits regressed in 60% of patients who had 
a median SAA concentration of less than 10 mg/L, and 
survival among these patients was superior to survival 
among those in whom amyloid deposits did not regress. 
Sustained increased concentration of SAA is the most 
significant risk factor in AA amyloidosis, whereas 
reduction of SAA concentration improves survival and 
is associated with arrest or even regression of amyloid 
deposits [7-9]. 
The degree of renal involvement is important, with 
patients who have elevated creatinine levels doing worse 
compared with patients with a normal creatinine levels. 
The pattern of renal involvement is also important. 
Specifically, glomerular involvement with amyloid and 
fibrosis appear to have clinical course characterized by 
deteriorating renal function compared to patients with 
other types of renal involvement. Generally, however the 
median survival is over 5 years [10, 11]. 
The CT findings of diffuse low-density nodal enlargement 
should prompt the possible diagnosis of associated 
amyloidosis, Lymph node involvement occurs in up to 
37% of patients with systemic amyloidosis .The hilar, 
mediastinal, and para-aortic lymph nodes are most 
commonly involved [12]. Hodgkin lymphoma as a cause 
of secondary amyloidosis was excluded in this case by 
doing fine lymph node aspiration and biopsy.
Although amyloidosis secondary to collagen disease, 
in particular to Behcet’s disease, is frequently reported, 
rheumatic heart disease (RHD) with amyloidosis is rare 
[13]. Paydas reported 59 patients with renal amyloidosis, 
one of whom had rheumatic heart disease who had been 
operated for mitral stenosis 14 years before [14].
In our case there was no clinical evidence of rheumatoid 
arthritis, inflammatory bowel disease, tuberculosis or 
malignancy. The patient’s secondary amyloidosis and 
lymphdenopathy was presumed to be related to the long 
standing rheumatic heart disease. 
Conclusion
A long standing inflammatory process such as RHD can 
lead to secondary AA amyloidosis.
was discovered accidentally to have proteinuria and rising 
serum creatinine, while he was being prepared for mitral 
valve replacement. He had no history of diabetes mellitus, 
hypertension or tuberculosis. Physical examination 
revealed a well-developed male, with a blood pressure of 
115/70 mm Hg, heart rate of 85 bpm and no raised jugular 
venous pressure. He had no palpable lymphadenopathy, 
apart from a small left inguinal lymph node. Examination 
of the lungs revealed normal vesicular breathing. Heart 
examination revealed a pansystolic murmur over the apex 
propagated to the axilla. There was no rub and no gallop. 
In the abdomen, the liver, spleen and kidneys were not 
palpable. There was no lower limb edema.
His laboratory data were as follows: hemoglobin 11 g/
dL, WBCs 4.6x109/uL, hematocrit 36%, platelet count 
285x109/uL, serum creatinine 1.2 mg/dL, blood urea 
80.6 mg/dL, 24 hour urine protein 18 g/day, creatinine 
clearance 68 ml/min/1.7m2. His serum aspartate 
aminotransferase (AST) was 18 U/L (normal range, 
10–40 U/L); alanine aminotransferase (ALT) 16 U/L 
(normal range, 10–45 U/L), serum albumin 35 g/L, 
total calcium 8.8 mg/dL, ESR 54 mm/hr. Urinalysis 
revealed 4+ proteinuria and a bland sediment. Purified 
protein derivative (PPD) test was negative. Hepatitis C 
antibody and hepatitis B surface antigen were negative. 
All other relevant serological studies were negative 
or normal, including antinuclear antibody (ANA), 
antineutrophil cytoplasmic antibody (ANCA), and C3 
and C4 complement levels. Serum and urinary protein 
electrophoresis were normal; there was no evidence of 
monoclonal antibodies in the serum or urine.
A chest radiograph showed clear lung fields with cardiac 
enlargement; electrocardiogram (ECG) revealed normal 
rhythm and voltage, an echocardiography revealed 
mitral stenosis, mitral regurgitation, severe pulmonary 
hypertension, left ventricular ejection fraction (LVEF) 
56% and no evidence of infiltrative disease. Abdominal 
ultrasound showed normal kidneys size, and maintained 
cortico- medullary differentiation. CT chest and abdomen 
revealed bilateral hilar and mediastinal lymphadenopathy 
and para-aortic lymph nodes. Endobronchial biopsy and 
bronchoalveolar lavage revealed non-specific chronic 
inflammatory changes and no evidence of acid fast 
bacilli. Fine needle aspiration of mediastinal lymph 
nodes revealed no malignancy or metastatic lesions, 
Congo red stain not done because the amyloid protein 
is deposited extracellularly and fine needle aspiration 
revealed cellular elements only. Transbronchial biopsy 
of mediastinal lymph nodes revealed no malignancy or 
metastatic lesions, but revealed amyloid deposits with 
the Congo red stain, as well as chronic inflammation. 
Bone marrow examination was normal.
Kidney biopsy recovered two cores of tissue, showing 
16 glomeruli. The glomeruli showed diffuse mesangial 
and nodular deposits of amorphous hyaline material 
with focal near complete glomerular obliteration. 
The tubules showed vacuolization and there was mild 
interstitial inflammation. There was 30% tubular 
atrophy and interstitial fibrosis. Renal vessels  showed 
deposit of amorphous hyaline material, the deposits 
showed apple green birefringence on Congo red 
stain and lost the birefringence on pretreatment with 
potassium permanganate (Kmno4) [Fig-1; A and B]. 
Immunohistochemical stains for IgA, IgG, IgM, C3, 
C4, Kappa and Lambda light chains were negative. The 
pathological diagnosis was secondary AA amyloidosis.
Fig.1A                                                         Fig.1B
Figure-1: AA (amyloid A) amyloidosis. A: positive Congo red staining of the amyloid deposits in the mesangium and arterial 
walls. B: Pretreatment with potassium permanganate eliminates Congo red staining proving the AA nature of the amyloid.
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(apoA1) from the HDL particles and facilitates HDL-
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Several lines of evidence have indicated that the 
conversion of SAA into amyloid fibrils occurs through its 
specific interaction with heparan sulphate, a ubiquitously 
expressed glycosaminoglycan component of the 
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revealed a well-developed male, with a blood pressure of 
115/70 mm Hg, heart rate of 85 bpm and no raised jugular 
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pathological diagnosis was secondary AA amyloidosis.
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Figure-1: AA (amyloid A) amyloidosis. A: positive Congo red staining of the amyloid deposits in the mesangium and arterial 
walls. B: Pretreatment with potassium permanganate eliminates Congo red staining proving the AA nature of the amyloid.
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